Adult T-cell lymphoma/leukaemia is a rare and challenging blood cancer linked to a viral infection that can remain silent for decades before transforming into an aggressive disease, requiring treatment approaches that vary widely depending on how rapidly it progresses and how extensively it affects the body.

Understanding Treatment Approaches for a Complex Disease

Treatment for adult T-cell lymphoma/leukaemia, commonly known as ATLL, must be carefully tailored to each patient’s unique situation. This blood cancer, which develops in a specific type of white blood cell called T-cells, behaves very differently depending on its subtype. Some forms grow slowly and may not require immediate intervention, while others progress rapidly and demand urgent, intensive treatment.^[1] The main goals of treatment include controlling symptoms, slowing disease progression when possible, and improving quality of life, though achieving long-term control remains challenging for many patients.

The disease presents in four distinct clinical forms, each requiring its own treatment strategy. The smoldering and chronic subtypes grow slowly and may cause only mild symptoms, such as minor skin changes. In contrast, the acute and lymphomatous subtypes are aggressive, meaning they grow and spread quickly throughout the body, affecting lymph nodes, blood, skin, and internal organs.^[2] Treatment decisions depend heavily on which subtype a person has, how fit they are to tolerate aggressive therapies, and whether the goal is to manage the disease long-term or to pursue potentially curative treatments like stem cell transplantation.

Because ATLL is rare, particularly outside regions where the virus that causes it is common, large-scale clinical trials have been difficult to conduct. This means that much of what doctors recommend comes from smaller studies, expert experience, and ongoing research into new treatment approaches.^[12] Patients with ATLL often face significant challenges, as aggressive forms of the disease can be resistant to standard cancer treatments and cause severe weakening of the immune system, making infections a serious concern.

Standard Treatment Options for ATLL

For patients diagnosed with slow-growing subtypes of ATLL—specifically smoldering or favorable chronic forms—doctors often recommend an approach called active surveillance, also known as watchful waiting. This means the patient does not receive treatment immediately but is monitored closely through regular physical examinations and periodic imaging tests like CT scans to check for swollen lymph nodes or organ enlargement. Treatment begins only if symptoms appear or the disease shows signs of progressing.^[9] This approach recognizes that in some patients, the disease may remain stable for years without causing significant problems, and unnecessary treatment can be avoided.

When slow-growing forms do require treatment, a combination of antiviral medications has shown promising results. The standard regimen combines zidovudine, also called AZT (an antiviral drug originally developed for HIV), with interferon-alpha, a protein that helps the immune system fight viruses and cancer cells. This combination works by targeting the virus that drives the disease and by stimulating the body’s own defenses. Studies have shown that this antiviral therapy can significantly prolong survival in patients with smoldering and chronic ATLL subtypes.^[10] Patients typically need to continue this treatment for extended periods, and doctors monitor them regularly for side effects and disease response.

For patients with skin involvement from ATLL, doctors may prescribe skin-directed therapies. These include topical steroids applied directly to affected areas or localized radiation therapy, which delivers focused radiation doses only to diseased skin regions. These approaches can control skin symptoms without subjecting the entire body to systemic treatment.^[9] They are particularly useful for managing discomfort and visible skin changes that affect quality of life.

Aggressive subtypes of ATLL—the acute and lymphomatous forms—require much more intensive treatment. The standard approach uses chemotherapy, which refers to powerful drugs that kill rapidly dividing cancer cells throughout the body. Common chemotherapy regimens for ATLL include combinations of several drugs given together. One frequently used combination is called CHOP, which stands for cyclophosphamide, doxorubicin (also known as hydroxydaunorubicin), vincristine (trade name Oncovin), and prednisone (a steroid). Other regimens add additional drugs to this backbone, such as etoposide in the CHOEP or dose-adjusted EPOCH regimens, or alternate with high doses of methotrexate and cytarabine in the Hyper-CVAD protocol.^[9]

These chemotherapy combinations work by attacking cancer cells at different points in their growth cycle, increasing the chance that the treatment will be effective. However, chemotherapy also affects normal, healthy cells that divide rapidly, such as those in the bone marrow, digestive tract, and hair follicles. This leads to common side effects including low blood cell counts (which increase infection risk and cause fatigue), nausea and vomiting, mouth sores, hair loss, and increased susceptibility to infections. Patients receiving these intensive regimens require close monitoring and supportive care to manage side effects.

Another important treatment category combines chemotherapy with immunotherapy—drugs that harness or enhance the body’s immune system to fight cancer. One specific type is called an antibody-drug conjugate, or ADC. These are laboratory-made antibodies that recognize and attach to specific proteins on cancer cells, carrying a chemotherapy drug directly to the tumor. Once the antibody binds to the cancer cell, it delivers the chemotherapy inside, where it kills the cell from within. The combination called BV-CHP uses the antibody-drug conjugate brentuximab vedotin (brand name Adcetris) along with cyclophosphamide, doxorubicin, and prednisone. This treatment is used specifically for lymphomas that are positive for a protein called CD30 on their surface.^[9]

For many patients with aggressive ATLL, the ultimate goal is to proceed to allogeneic hematopoietic stem cell transplantation, often shortened to alloHSCT or simply stem cell transplant. This procedure involves using high-dose chemotherapy to eliminate the patient’s diseased bone marrow and immune system, then replacing it with healthy stem cells donated by another person (the allogeneic donor). These donor cells can create a new, healthy immune system that may also recognize and attack any remaining cancer cells. Stem cell transplantation is currently the only treatment approach that offers the possibility of long-term survival or even cure for aggressive ATLL.^[12] However, it carries significant risks, including severe infections, graft-versus-host disease (where the donor cells attack the patient’s body), and other serious complications. Only patients who are fit enough to tolerate the procedure are considered candidates.

Emerging Treatments in Clinical Trials

Researchers around the world are actively testing new drugs and treatment approaches for ATLL in clinical trials. These studies aim to find therapies that are more effective and less toxic than current options, particularly for aggressive forms of the disease that have proven difficult to control.

One of the most promising drugs currently being studied is mogamulizumab. This is a type of immunotherapy called a monoclonal antibody, which is a laboratory-created protein designed to target a specific molecule on cancer cells. Mogamulizumab specifically binds to a protein called CCR4, which is found on the surface of ATLL cells. By attaching to this protein, the antibody marks the cancer cells for destruction by the immune system and may also directly interfere with signals that help the cancer cells survive and spread.^[10][17] Clinical trials have shown that mogamulizumab can produce responses in patients with ATLL, and it has generated significant interest as a targeted therapy that specifically attacks cancer cells while potentially sparing normal tissues.

Another drug showing promise in clinical studies is lenalidomide, a medication that belongs to a class of drugs that modulate the immune system and have direct effects on cancer cells. Lenalidomide appears to work through multiple mechanisms: it can directly interfere with cancer cell growth, enhance the body’s immune response against tumors, and affect the environment around cancer cells that supports their survival. Research has demonstrated that lenalidomide has activity against ATLL cells, offering another potential option for patients whose disease has not responded to other treatments.^[10][17]

Clinical trials testing new treatments typically progress through three phases. Phase I trials focus primarily on safety, determining what doses can be given without causing unacceptable side effects. Phase II trials assess whether the treatment actually works—whether it can shrink tumors, control disease progression, or improve symptoms. Phase III trials compare the new treatment directly against current standard treatments to determine if it offers advantages in terms of effectiveness or side effects.^[12] For ATLL, trials are being conducted in multiple countries, including Japan (where ATLL is most common), the United States, and various European nations.

Researchers are also investigating treatments that target the specific biological processes that drive ATLL development. Because the disease is caused by HTLV-1 viral infection, scientists are studying drugs that interfere with viral proteins that promote cancer development. Two viral proteins in particular, called Tax and HBZ, play crucial roles in transforming normal T-cells into cancer cells. Tax protein is involved in the initial cancer transformation, while HBZ protein is found in all infected cancer cells and drives their continued growth.^[2] Developing treatments that specifically target these viral proteins could offer a more precise approach to fighting ATLL.

Other experimental approaches being explored in research settings include drugs that interfere with specific molecular pathways inside cancer cells. These might include inhibitors of enzymes that cancer cells need to survive, drugs that affect how genes are turned on or off in cancer cells, or treatments that target the signals cancer cells use to communicate with their surroundings. As scientists learn more about the unique characteristics of ATLL cells at the molecular level, they can design increasingly targeted therapies.

Participation in clinical trials offers patients access to cutting-edge treatments before they become widely available. For ATLL patients, clinical trial participation is often strongly encouraged because the disease remains difficult to treat with currently approved therapies, particularly in its aggressive forms. Trials may be available at major cancer centers and research hospitals. Eligibility criteria vary by study but typically consider factors such as disease subtype, previous treatments received, overall health status, and specific characteristics of the patient’s cancer cells.^[12]

Most common treatment methods

• Active surveillance (watchful waiting)
  • Used for slow-growing smoldering and favorable chronic ATLL subtypes
  • Involves regular physical exams and periodic imaging without immediate treatment
  • Treatment begins only if symptoms develop or disease progresses
• Antiviral therapy
  • Combination of zidovudine (AZT) and interferon-alpha
  • Effective for smoldering and chronic ATLL subtypes
  • Targets the HTLV-1 virus and stimulates immune system response
  • Can significantly prolong survival in less aggressive forms
• Combination chemotherapy
  • CHOP regimen: cyclophosphamide, doxorubicin, vincristine, and prednisone
  • CHOEP: adds etoposide to CHOP
  • Dose-adjusted EPOCH: etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone
  • Hyper-CVAD: alternates cyclophosphamide, vincristine, doxorubicin, dexamethasone with high-dose methotrexate and cytarabine
  • Used for aggressive acute and lymphomatous subtypes
• Immunotherapy and targeted therapy
  • Brentuximab vedotin (antibody-drug conjugate) combined with chemotherapy for CD30-positive lymphomas
  • Mogamulizumab (monoclonal antibody targeting CCR4) being tested in clinical trials
  • Lenalidomide (immune-modulating drug) showing promise in research studies
• Skin-directed therapies
  • Topical steroids applied directly to affected skin areas
  • Local radiation therapy targeting specific skin lesions
  • Used to manage skin involvement without systemic treatment
• Allogeneic stem cell transplantation
  • High-dose chemotherapy followed by infusion of donor stem cells
  • Only potentially curative treatment for aggressive ATLL
  • Reserved for fit patients who respond to initial chemotherapy
  • Carries significant risks including infections and graft-versus-host disease